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Abstract
Background—The AmpliVue™ Trichomonas Assay (Quidel) is a new FDA cleared rapid test 
for qualitative detection of Trichomonas vaginalis (TV) DNA in female vaginal specimens. The 
assay is based on BioHelix’s Helicase-Dependent Amplification (HDA) isothermal technology in 
conjunction with a disposable lateral-flow detection device, with a total turn-around time of 
approximately 45 minutes.
Objective—The objective of this study was to compare the performance of this new assay to wet 
preparation and culture, as well as to another FDA cleared nucleic acid amplification assay.
Methods—Four clinician collected vaginal swabs were obtained from women attending STD, 
family planning, and OB/GYN clinics and tested by AmpliVue™ Trichomonas Assay and 
comparator tests: saline microscopy, TV culture (InPouch™), and Aptima® TV (ATV). 
AmpliVue™ Trichomonas Assay results were compared to a composite positive comparator 
(CPC) as determined by the results from culture and/or wet mount microscopic examination. At 
least one of either the wet preparation or culture reference test results was required to be positive 
to establish CPC.
Results—A total of 992 patients, 342 symptomatic and 650 asymptomatic patients, were 
included in the study. Results for AmpliVue for all women combined compared to saline 
microscopy and culture as a composite positive comparator yielded a sensitivity of 100%. 
Specificity for all women was 98.2%. Overall percent agreement versus Aptima® TV was 97.8%. 
Sensitivity for AmpliVue compared to Aptima® was 90.7% %, while specificity was 98.9%.
Conclusions—The rapid AmpliVue™ Trichomonas Assay performed as well as microscopy and 
culture, and had comparable sensitivity and specificity to another NAAT for the detection of TV. 
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This study provided evidence of new diagnostic options and indicated very good performance of 
amplified testing for detection of TV in symptomatic and asymptomatic women.
Keywords
Trichomonas vaginalis; trichomoniasis; Point-of Care Test; Rapid amplified diagnostic test; 
AmpliVue Trichomonas test
Introduction
Trichomoniasis is an infection caused by Trichomonas vaginalis (TV), a motile protozoan 
parasite. The World Health Organization estimates that there are 276.4 million new cases of 
trichomonas per year in adults between the ages of 15 and 49 in 2008.1 This sexually 
transmitted infection is the most prevalent nonviral sexually transmitted infection (STI), and 
is estimated to infect 3.7 million people in the United States.2 As such, these infections 
represent the most common curable STI in young, sexually active men and women.2
TV infections in women have been associated with poor reproductive outcomes such as low 
birth weight (LBW) and premature birth.3–5 In a cohort of over 13,000 women, there was an 
attributable risk of trichomonas associated with LBW in Blacks of 11% vs. 1.6% in 
Hispanics, and 1.5% in Whites.3 The National Health and Nutrition Examination Survey 
(NHANES) 2001–2004 estimated that 3.1% of women in the United States have TV.6 Data 
from the NHANES also demonstrated that TV was associated with other STIs among 
women in the U.S. population in a sample of 3,648 women, which represented a weighted 
sample of the experience of 65,563,298 women between the ages of 14 and 49 years.7 The 
prevalence of trichomoniasis in these women was 3.2% with over 80% of cases being 
asymptomatic. T. vaginalis infection is also associated with significantly increased risks of 
HIV acquisition (two to three-fold), and pelvic inflammatory disease (PID) among HIV-
infected women.8–11 Older age and health disparities are also prominent features in 
trichomonas epidemiology, affecting over 11% of women age ≥40 years and 13% of black 
women in the United States.12,13 T. vaginalis infection is not a notifiable infection to the 
Centers for Disease Control and Prevention in the United States.
Because this infection is very common, and can be associated with such serious adverse 
events, diagnostic testing for TV and treatment of TV infections are recommended for 
symptomatic women and men. For asymptomatic individuals, screening is only encouraged 
for all HIV positive women (symptomatic an asymptomatic), women attending HIV clinics, 
and persons in such locations as sexually transmitted disease (STD) clinics and correctional 
facilities.14
The conventional methods to detect T. vaginalis in vaginal swabs are wet mount microscopy 
and culture techniques. Wet mount microscopy is the most common method of T. vaginalis 
detection, and although this technique is rapid and inexpensive, it is only about 36 to 75% 
sensitive compared to culture even in the hands of trained microscopists.15 This sensitivity 
of culture method is less in studies than what can be achieved by nucleic acid amplification 
tests (NAATs).16 Thus, the use of more highly sensitive molecular tests is recommended for 
T. vaginalis detection in symptomatic women and men, since they have higher sensitivity 
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than culture. Among women, NAATs may detect a prevalence three to five-fold higher than 
wet preparation microscopy.4 Presently, there are two FDA cleared NAATs for the detection 
of trichomonas in women, the Aptima Trichomonas vaginalis assay (Hologic Gen-Probe, 
San Diego, CA)12 and the BD ProbeTec Qx Assay on the BD Viper System (Becton 
Dickinson, Sparks, Maryland).17
The objective of this study was to evaluate the performance of a new amplified molecular 
assay for the detection of T. vaginalis, the Isothermal Helicase-Dependent AmpliVue® 
Assay (Quidel, San Diego, CA).
Methods
Symptomatic women and asymptomatic women who were 14 years or older were enrolled 
from high and low prevalence clinics from five geographically diverse areas. The study was 
performed April to November 2014 at four locations in the United States and one location in 
Canada. Specimens were obtained from each subject after written informed consent was 
obtained. Inclusion Criteria included women who presented with symptoms of T. vaginalis 
and asymptomatic women who were scheduled for a pelvic examination or screening for T. 
vaginalis. Patient age or date of birth was obtained.
The study was conducted in accord with the Health Insurance Portability and Accountability 
Act (HIPAA) and approved by the associated Institutional Review Boards.
Laboratory Studies
Four clinician collected vaginal swabs were obtained and tested from women attending STD, 
family planning, and OB/GYN clinics. Swabs 1 and 2 were randomized for saline 
microscopy (wet mount) and culture (InPouch™ TV, BioMed Diagnostics, Inc., White City, 
Oregon). The saline microscopy was performed by the clinician immediately after the swab 
collection to examine for motile trichomonads under the microscopy as prescribed by local 
clinic protocols. Culture pouches were observed by laboratorians daily for 5 reads. Swab 3 
was tested by the AmpliVue Trichomonas assay in participating laboratories. Swab 4 was 
tested by a FDA cleared NAAT according to manufacturer’s instructions (Aptima TV, Gen-
Probe/Hologic, San Diego, CA). The AmpliVue Trichomonas Assay results were first 
compared to a composite positive comparator (CPC) as determined by the results from 
saline microscopic examination and/or culture comparator tests. At least one of these two 
assays was required to be positive to establish a CPC. Results of the AmpliVue Trichomonas 
were also compared to the NAAT.
To detect T. vaginalis directly from vaginal swab specimens in symptomatic and 
asymptomatic women, the assay targets a conserved repeat sequence of the T. vaginalis 
DNA. The technology utilized isothermal helicase dependent amplification (HDA), which 
uses a helicase to separate DNA. With a total turn-around time of approximately 45 minutes, 
the assay combines three steps: 1) sample preparation with one-step dilution/heating in a 
small heat block for lysis for 10 min at 95°C (Figure 1); 2) isothermal DNA amplification of 
target sequences specific to T. vaginalis in a small heat block for 25 minutes at 64°C by 
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HDA; and 3) lateral-flow strip based colorimetric detection in a self-contained, disposable 
device (Figure 1).
Quality Control
The AmpliVue™ Trichomonas Assay incorporated several controls to monitor assay 
performance: 1) The internal control was used to detect HDA inhibitory specimens and to 
confirm the integrity of assay reagents and cassette detection. The internal control was 
included in the reaction tubes. 2) The External assay positive control, provided separately, 
was used to confirm the ability of the assay to detect T. vaginalis DNA and was intended to 
monitor substantial reagent and cassette failure. 3) The external assay negative control was 
used to detect reagent or environment contamination or carry-over by either T. vaginalis 
DNA or amplicons. Laboratory-grade water was used to set up the external negative control 
assays and was treated as a patient specimen.
Quality Control testing was conducted in accordance with the Instructions for Use. The 
reactivity of each new lot and each new shipment of the AmpliVue™ Trichomonas Assay 
was verified on receipt and before use. On each testing day, at least one study technician 
from each laboratory tested all lots of AmpliVue™ Trichomonas Assays to be used in that 
day by setting up positive and negative control assays with AmpliVue™ Trichomonas 
external positive controls and laboratory-grade water.
Statistical analysis was performed by SAS version 9, (Cary, NC). We calculated sensitivity, 
specificity, positive predictive and negative predictive values, percent agreement, and a 
kappa statistic.
Results
Clinician-collected vaginal swab specimens were obtained from asymptomatic (n=650) or 
symptomatic (n=342) women (total 992) These were tested by the composite positive 
comparator methods and the AmpliVue® Trichomonas Assay, as well as the Aptima assay. 
Table 1 shows the ages and the numbers of asymptomatic and symptomatic women enrolled 
by site. The prevalence of T. vaginalis by absence or presence of symptoms was 
asymptomatic - 9.4%, symptomatic - 17.3% and for all women - 12.1%. Of the patients 
enrolled, 8 specimens generated invalid results upon initial testing with the AmpliVue® 
Trichomonas Assay (0.8%). These specimens were re-tested according to the instructions 
provided in the package insert. Six (6) of these specimens generated valid results upon re-
testing (5 negative and 1 positive result), and two (2) specimens generated a second invalid 
result (0.2%). Table 2 shows the sensitivity, specificity, PPV, and NPV (100%, 98.2%, 
88.2%, and 100%, respectively) of the AmpliVue® Trichomonas Assay compared to the 
composite reference methods of saline microscopy/culture (CPC).
Overall percent agreement versus Aptima TV was 97.8% (Cohen’s kappa= 90.7); 97.1% for 
symptomatic women; 97.7% for asymptomatic women. There were 16 discordant specimens 
(AmpliVue Positive/Composite Reference Method Negative), eight (8) of these specimens 
were positive by the FDA-cleared Aptima TV molecular assay. Sensitivity for AmpliVue 
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compared to Aptima was 90.7% overall (90.1% for symptomatic and 87.2% for 
asymptomatic women) (Table 3).
Discussion
AmpliVue TV showed high sensitivity (100%) and specificity (98.2%) compared to the 
standard tests of saline microscopy and culture, regardless of symptoms. Additionally, 
AmpliVue TV demonstrated high agreement compared to Aptima TV with an overall 
agreement of 97.8%. Although there are now two FDA cleared NAAT assays for 
trichomonas, and it is generally accepted that NAATs for TV are more sensitive than culture, 
the reference standard set by the FDA for this study trial was saline microscopy and culture, 
which we refer to as the composite positive comparator (CPC). The single NAAT selected 
for additional comparison was performed over and above the input from the FDA with this 
fact in mind. Thus the study deign and the CPC used may have impacted the original point 
estimates. By also comparing the results of the AmpliVue to another NAAT assay, we 
believe we have also compared the assay to a higher standard than that of culture and saline 
microscopy. However, we were not able to ascertain whether the AmpliVue assay would be 
more accurate than the OSOM assay16 since it was studied in this trial.
Although the rapid AmpliVue assay appeared to perform better than saline microscopy/
culture by detecting more positive results than the defined CPC, only 8 of the 16 discordant 
samples were confirmed as positive when a “tie-breaker” NAAT assay was performed, 
suggesting that half of the discordant AmpliVue specimens may have been false positives. 
Alternatively, the 8 of the 16 discordant samples that were positive by a NAAT assay would 
improve the specificity, if these data were included in the calculation of the specificity of the 
AmpliVue test. However, a limitation of the study design was that the swab for the Aptima 
TV was obtained as the 4th swab. Randomization of the last two swabs was not performed 
and may have contributed to the inability to confirm the AmpliVue positive results for the 8 
samples that were Aptima TV negative.
There are additional limitations to the interpretation of our study with regard to 
interpretation of results. The use of saline microscopy and culture as the reference standard 
may have artificially inflated the point estimates of sensitivity and specificity; thus they may 
have been lower if the NAAT assay was also used in the composite reference methods. There 
may also have been delays in incubating cultures and reading saline microscopy tests, 
transportation delays or variability in interpretation of the results of these comparator assays, 
both of which are subjective in nature. The possibility of false positives by the NAAT test 
cannot be ruled out, but they are highly unlikely since the platform is a closed and robotic 
platform, which can eliminate cross contamination by a laboratorian.
This rapid assay demonstrated that an amplified molecular assay can perform as well as 
saline microscopy/culture and provided comparable results as another FDA cleared NAAT 
assay while yielding results in real time. This study provided evidence of new diagnostic 
options and indicates the performance of a new amplified testing method for detection of 
trichomoniasis in symptomatic and asymptomatic women in 45 minutes, demonstrating 
rapid turn-around-time. The AmpliVue Trichomonas Assay identified all of the culture and 
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saline microscopy positive cases of trichomonas infections and substantially more than 
culture saline microscopy, as shown by detecting additional confirmed positives and the 
strong agreement with Aptima TV NAAT assay. It is now FDA cleared as moderately 
complex, but its potential to be CLIA waived in the future may increase its usefulness as a 
point-of-care (POC) test that can be used for treatment of patients before they leave the 
clinic. It appeared to yield a similar sensitivity in this study to another rapid, commercially 
available unamplified antigen trichomonas assay, when the confidence intervals are 
considered.16 The sensitivity for trichomonas compared to what is achieved in the 
trichomonas component of the Affirm vaginitis test is also much higher.18–19
As more data accumulate for the association of trichomonas infections with adverse events, 
such as HIV transmission and perinatal morbidity, and as new testing methods become more 
widely available, it seems prudent to advocate for more public health recognition with more 
testing for trichomonas and further modeling studies of its potential treatment impact to 
improve health outcomes.11,20–25
In summary, the rapid AmpliVue® Trichomonas Assay showed a high sensitivity and 
specificity in both asymptomatic (100%/98.3%) and symptomatic (100%/97.9%) women in 
45 minutes of test time, when compared to the composite reference method that included 
saline microscopy and InPouch TV culture.
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Figure 1. 
Schematic of the AmpliVue Trichomonas vaginalis assay.
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Table 1
Age and symptomatic status of women in the AmpliVue trial for the detection of Trichomonas vaginalis in 
vaginal specimens.
Age Total Asymptomatic Symptomatic
14–19 64 (6.5%) 38 (5.9%) 26 (7.6%)
20–24 263 (26.6%) 157 (24.2%) 106 (31.0%)
25–29 179 (18.1%) 104 (16.0%) 75 (31.9%)
≥30 484 (48.9%) 349 (53.9%) 135 (39.5%)
Total women 990 648 342
UAB 296 (29.9%) 133 (44.9%) 163 (55.1%)
JHU 115 (11.6%) 46 (40%) 69 (60%)
UW 248 (25.1%) 207 (83.5%) 41 (16.5%)
MU 295 (29.8%) 260 (88.1%) 35 (11.9%)
UNC 36 (3.6%) 2 (5.6%) 34 (94.4%)
UAB, University of Alabama at Birmingham; JHU, Johns Hopkins University, UW, University of Washington, MU, McMaster University; UNC, 
University of North Carolina.
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